AU Patent

AU2021260934A1 — Bifunctional molecules and methods of using thereof

Assigned to Flagship Pioneering Inc · Expires 2022-11-24 · 3y expired

What this patent protects

The present disclosure relates generally to compositions of synthetic bifunctional molecules comprising a first domain that specifically binds to a target ribonucleic acid and a second domain that specifically binds to a target polypeptide, and uses thereof.

USPTO Abstract

The present disclosure relates generally to compositions of synthetic bifunctional molecules comprising a first domain that specifically binds to a target ribonucleic acid and a second domain that specifically binds to a target polypeptide, and uses thereof.

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

Patent Metadata

Patent number: AU2021260934A1
Jurisdiction: AU
Classification: —
Expires: 2022-11-24
Drug substance claim: No
Drug product claim: No
Assignee: Flagship Pioneering Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.